Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dasatinib - Bristol-Myers Squibb

Drug Profile

Dasatinib - Bristol-Myers Squibb

Alternative Names: BMS-354825; Sprycel

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; City of Hope National Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital; Otsuka Pharmaceutical; Sarcoma Alliance for Research through Collaboration; University of Texas M. D. Anderson Cancer Center; Weill Cornell Medical College
  • Class Amides; Antineoplastics; Chlorobenzenes; Piperazines; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase III Prostate cancer
  • Phase II Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Myeloproliferative disorders; Sarcoma
  • Phase I/II Glioblastoma; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Malignant-mesothelioma; Waldenstrom's macroglobulinaemia
  • No development reported Colorectal cancer; Leukaemia; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer
  • Discontinued Pancreatic cancer; Scleroderma

Most Recent Events

  • 31 Oct 2022 Dasatinib is still in phase I trials for Mesothelioma in USA (NCT00652574)
  • 11 Oct 2022 Bristol-Myers Squibb completes a phase II trial in Chronic myeloid leukaemia and acute lymphoblastic leukaemia (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT00529763)
  • 07 Oct 2022 Bristol-Myers Squibb and M. D. Anderson Cancer Center, the Department of Defense completes a phase I trial for Malignant mesothelioma (First-line therapy, Early-stage disease, Mid-stage disease) in USA (NCT00652574)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top